First Time Loading...

Sartorius Stedim Biotech SA

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
Price: 226 EUR +2.36% Market Closed
Updated: Oct 1, 2023

Intrinsic Value

Intrinsic Value History
Sartorius Stedim Biotech SA

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Sartorius Stedim Biotech SA's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis


Balance Sheet Decomposition
Sartorius Stedim Biotech SA

Current Assets 1.6B
Cash & Short-Term Investments 134m
Receivables 350m
Other Current Assets 1.1B
Non-Current Assets 3.6B
Long-Term Investments 24.4m
PP&E 1.5B
Intangibles 2B
Other Non-Current Assets 60.2m
Current Liabilities 922m
Accounts Payable 440m
Accrued Liabilities 81.1m
Other Current Liabilities 401m
Non-Current Liabilities 1.7B
Long-Term Debt 1.3B
Other Non-Current Liabilities 364m
Fundamental Scores

DIM Profitability Score
Profitability Due Diligence

Sartorius Stedim Biotech SA's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Year Average ROE
Exceptional ROE
Exceptional 3-Years Revenue Growth

Sartorius Stedim Biotech SA's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

DIM Solvency Score
Solvency Due Diligence

Sartorius Stedim Biotech SA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency

Sartorius Stedim Biotech SA's solvency score is 74/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DIM Price Targets Summary
Sartorius Stedim Biotech SA

Wall Street analysts forecast DIM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DIM is 310.49 EUR with a low forecast of 272.7 EUR and a high forecast of 409.5 EUR.

Price Target
272.7 EUR
21% Upside
Price Target
310.49 EUR
37% Upside
Price Target
409.5 EUR
81% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

DIM Return Decomposition
Main factors of price return

What is price return decomposition?

DIM Price
Sartorius Stedim Biotech SA

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
+1 174%
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 52.09%
Standard Deviation of Annual Returns 56.37%
Max Drawdown -61%
Shares Statistics
Market Capitalization 20.8B EUR
Shares Outstanding 92 167 279
Percentage of Shares Shorted

Company Profile

Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA




Life Sciences Tools & Services

Market Cap

20.8B EUR

Dividend Yield



Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,409 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.


Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex




10 409


Chairman & CEO
Dr. Joachim Kreuzburg
VP of Group Financing & Investor Relations
Mr. Heiko Imöhl
Head of Corp. Communications & IR
Ms. Petra Kirchhoff
Exec. VP of Marketing, Sales & Services for Lab Products and Services Division
Mr. John Gerard Mackay
Head of Investor Relations
Benedikt Orzelek
Head of Controlling BPS
Olivier Guitard

See Also

Other Stocks
What is the Intrinsic Value of one DIM stock?

The intrinsic value of one DIM stock under the Base Case scenario is 252.11 EUR.

Is DIM stock undervalued or overvalued?

Compared to the current market price of 226 EUR, Sartorius Stedim Biotech SA is Undervalued by 10%.